Literature DB >> 20345334

Systemic treatment in breast-cancer patients with brain metastasis.

Cagatay Arslan1, Omer Dizdar, Kadri Altundag.   

Abstract

IMPORTANCE OF THE FIELD: Breast cancer is the second most common cause of CNS metastasis, following lung cancer. With better control of systemic disease, the CNS is emerging as a sanctuary site of relapse in patients with otherwise controlled cancer. AREAS COVERED IN THIS REVIEW: Standard therapy for brain metastasis is currently whole-brain radiotherapy. Other treatment modalities include surgery and radiosurgery in selected cases, corticosteroids, and systemic chemotherapy. Little progress has been made in chemotherapy for the treatment of brain metastases, partly because tumors develop brain metastases at a stage when they become totally chemoresistant. Nevertheless, new treatment choices have emerged considering cytotoxic and biological agents for the treatment of CNS metastases in patients with breast cancer. WHAT THE READERS WILL GAIN: In this review, we aimed to review current and future treatment options in the systemic treatment of brain metastases of breast cancer. TAKE HOME MESSAGE: Corticosteroids, anti-epileptic drugs, and radiotherapy remain the cornerstones of management. The efficacy of conventional cytotoxic chemotherapeutics is limited. Novel biologic agents, lapatinib being the most promising, are currently investigated in the treatment of brain metastases of breast cancer with promising results.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20345334     DOI: 10.1517/14656561003702412

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  23 in total

Review 1.  Treatment of brain metastases: chemotherapy.

Authors:  Sean A Grimm
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

Review 2.  Chemoprevention for brain metastases.

Authors:  Van A Trinh; Wen-Jen Hwu
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

Review 3.  Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier.

Authors:  Ankit I Mehta; Adam M Brufsky; John H Sampson
Journal:  Cancer Treat Rev       Date:  2012-06-22       Impact factor: 12.111

4.  A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients.

Authors:  Hiroji Iwata; Masaru Narabayashi; Yoshinori Ito; Shigehira Saji; Yasuhiro Fujiwara; Shigeyuki Usami; Koichi Katsura; Yasutsuna Sasaki
Journal:  Int J Clin Oncol       Date:  2012-07-19       Impact factor: 3.402

Review 5.  Preclinical approaches to study the biology and treatment of brain metastases.

Authors:  William Cruz-Muñoz; Robert S Kerbel
Journal:  Semin Cancer Biol       Date:  2010-12-13       Impact factor: 15.707

6.  Clinical pathology of metastatic gastric carcinoma to the breast: A report of two cases and a review of literature.

Authors:  Qiuhong Tian; Jinsheng Zeng; Xueqin Tao; Zhanmin Zhang; Xiaodong Zhou; Yiting Wang
Journal:  Oncol Lett       Date:  2016-03-17       Impact factor: 2.967

7.  Up-regulation of microRNA-10b is associated with the development of breast cancer brain metastasis.

Authors:  Aamir Ahmad; Seema Sethi; Wei Chen; Rouba Ali-Fehmi; Sandeep Mittal; Fazlul H Sarkar
Journal:  Am J Transl Res       Date:  2014-07-18       Impact factor: 4.060

8.  miR-509 suppresses brain metastasis of breast cancer cells by modulating RhoC and TNF-α.

Authors:  F Xing; S Sharma; Y Liu; Y-Y Mo; K Wu; Y-Y Zhang; R Pochampally; L A Martinez; H-W Lo; K Watabe
Journal:  Oncogene       Date:  2015-02-09       Impact factor: 9.867

9.  Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy.

Authors:  José Pablo Leone; Adrian V Lee; Adam M Brufsky
Journal:  Cancer Med       Date:  2015-03-09       Impact factor: 4.452

Review 10.  Breast cancer brain metastases: the last frontier.

Authors:  José Pablo Leone; Bernardo Amadeo Leone
Journal:  Exp Hematol Oncol       Date:  2015-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.